Home Table of Contents

016.04.2-VIII. ADMISSION CRITERIA

AR ADC 016.04.2-VIIIArkansas Administrative Code

West's Arkansas Administrative Code
Title 016. Department of Human Services
Division 04. Division of Behavioral Health
Rule 2. Methadone/Laam Treatment Program Standards
Ark. Admin. Code 016.04.2-VIII
016.04.2-VIII. ADMISSION CRITERIA
Currentness
A. The Program shall verify the applicant's name, address, date of birth and other critical identifying data.
B. The Program shall document a one (1) year history of addiction and current physiological dependence. A one (1) year history of addiction means a period of continuous or episodic addiction for the one (1) year period immediately prior to application for admission to the Program. Documentation may consist of the applicant's past treatment history, with the presence of clinical signs of addiction, such as, old and fresh needle marks, constricted or dilated pupils, or an eroded or perforated nasal septum.
C. For applicants who are under the age of eighteen (18) the Program shall document two (2) unsuccessful attempts at drug-free treatment, prior to being considered for admission to a Program. Note: No person under the age of eighteen (18) years of age may be admitted to maintenance treatment unless a parent, legal guardian, or responsible adult designated by the relevant state authority consents in writing to such treatment. No individual under age eighteen (18) is to receive LAAM.
D. The Program shall give admission priority to pregnant women (see XI page 8).
E. At the time of admission, each patient shall be informed of his or her rights in a language that he/she understands, including, as appropriate, American Sign Language, and shall receive a written copy of these rights, which shall include:
(1) The right to be fully informed, as evidenced by a patient's written acknowledgment, at the time of admission and during treatment, of the rights and responsibilities set forth herein and of all the rules and regulations governing patient conduct and responsibilities;
(2) The right to the receipt of adequate and humane services, regardless of sources of financial support;
(3) The right to the receipt of services within the least restrictive environment possible;
(4) The right to an individual treatment plan;
(5) The right to participate in the planning of his/her treatment plan and to treatment based on same;
(6) The right to periodic staff review of the patient's treatment plan;
(7) The right to an adequate number of competent, qualified and experienced professional clinical staff to implement and supervise the treatment plan;
(8) The right to be informed of treatment alternatives or alternative modalities;
(9) The right to be informed about potential adverse reactions to medication, including those reactions which might result from interactions with other prescribed or over-the-counter pharmacological agents, other medical procedures, and food;
(10) The right to give written consent whenever special equipment, such as two-way mirrors or cameras, are to be used. However, clients that refuse to provide such consent may be denied admission into the Program;
(11) The right to be encouraged and assisted throughout treatment to understand and exercise his/her rights as a patient and a citizen, including:
(a) The right to report any cases of suspected abuse, neglect, exploitation of patients being served in the program, in accordance with applicable State law and abuse reporting procedures;
(b) The right to a grievance and appeal process; and
(c) The right to recommend changes in policies and services;
(12) The right to be informed regarding the financial aspects of treatment, including the consequences of nonpayment of required fees;
(13) The right to be informed of the extent to and limits of confidentiality, including the use of identifying information for central registry and/or program evaluation purposes;
(14) The right to receive a copy of a consent for a release of confidential information after the form is signed by the patient; and
(15) The right to give informed consent prior to being involved in research projects.
The Medical Director may refuse treatment with a narcotic drug to a particular patient if, in the reasonable clinical judgment of the Medical Director, the patient would not benefit from such treatment. Prior to such a decision, appropriate staff may be consulted, as determined by the Medical Director.
Current with amendments received through February 15, 2024. Some sections may be more current, see credit for details.
Ark. Admin. Code 016.04.2-VIII, AR ADC 016.04.2-VIII
End of Document